👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
✓ Verified
Trust score 98/100
Accepting new patients
Prof
Prof Mark Beresford
Oncology
English
10,556+
Patients seen
14
Years in practice
7
Publications
1
Languages spoken
About
Professor Mark Beresford is a Consultant Clinical Oncologist working at the Royal United Hospital Bath, specialising in breast and urological malignancies.
Professor Beresford undertook his initial medical training at Gonville and Caius College, Cambridge University (1989-1992) before moving on to Oxford University for clinical training (1992-1995). Mark then moved to London for his junior doctor and specialist oncology training at St Mary's, University College, Charing Cross and Mount Vernon Hospitals. His passion for medical research led him to receive a Doctorate of Medicine from Oxford University for research into predicting response to chemotherapy in breast cancer and was awarded the Frank Doyle Medal for the highest mark in the Royal College of Radiologists oncology fellowship exams; a trajectory of excellence he has continued on throughout his career.
Mark was appointed as a consultant in oncology at University Hospital Bristol in 2006, moving his NHS practice to Royal United Hospital Bath in 2011. He is active in clinical research at a national level, being principal investigator on many trials and an active member of the National Cancer Research Institute Breast Cancer Clinical Studies Group since 2010. He is an Honorary Senior Lecturer at Bristol University and Visiting Researcher at Bath University and has been awarded grants for local clinical trials. He is particularly interested in methods for early assessment of benefit from treatment.
Mark has advised NICE on the adoption and appraisal of new chemotherapy drugs, is a committee member of the British Uro-oncology Group and the Penny Brohn complimentary therapy centre. He is also a member of Innovators in Breast Cancer and Action for Bladder Cancer groups. He has personally authored over 50 scientific journal articles, conference posters and textbook chapters. Professor Beresford is renowned in his field and there are few better qualified clinicians to see patients in private practice.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Radiotherapy
• Breast cancer
• Kidney (renal) cancer
• Prostate disease including prostate cancer
• Urological oncology
• Bladder cancer
• Brain tumours
Professor Beresford undertook his initial medical training at Gonville and Caius College, Cambridge University (1989-1992) before moving on to Oxford University for clinical training (1992-1995). Mark then moved to London for his junior doctor and specialist oncology training at St Mary's, University College, Charing Cross and Mount Vernon Hospitals. His passion for medical research led him to receive a Doctorate of Medicine from Oxford University for research into predicting response to chemotherapy in breast cancer and was awarded the Frank Doyle Medal for the highest mark in the Royal College of Radiologists oncology fellowship exams; a trajectory of excellence he has continued on throughout his career.
Mark was appointed as a consultant in oncology at University Hospital Bristol in 2006, moving his NHS practice to Royal United Hospital Bath in 2011. He is active in clinical research at a national level, being principal investigator on many trials and an active member of the National Cancer Research Institute Breast Cancer Clinical Studies Group since 2010. He is an Honorary Senior Lecturer at Bristol University and Visiting Researcher at Bath University and has been awarded grants for local clinical trials. He is particularly interested in methods for early assessment of benefit from treatment.
Mark has advised NICE on the adoption and appraisal of new chemotherapy drugs, is a committee member of the British Uro-oncology Group and the Penny Brohn complimentary therapy centre. He is also a member of Innovators in Breast Cancer and Action for Bladder Cancer groups. He has personally authored over 50 scientific journal articles, conference posters and textbook chapters. Professor Beresford is renowned in his field and there are few better qualified clinicians to see patients in private practice.
Diseases, Medical Tests and Treatments
• Chemotherapy
• Radiotherapy
• Breast cancer
• Kidney (renal) cancer
• Prostate disease including prostate cancer
• Urological oncology
• Bladder cancer
• Brain tumours
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof Mark Beresford
Education & training
-
2002–2008 MD · Medicine and Surgery
-
2008–2012 Residency · Oncology
-
2012–2013 Fellowship · Subspecialty training
Career & appointments
-
2012-09–2013-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
AmTrust Europe · 5,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 393 |
| Annual physical exam | 99395 | 2,415 |
| Vaccination administration | 90471 | 2,423 |
| Minor procedure (skin) | 17110 | 656 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 60 min | in_clinic | 270.00 EUR |
| Minor procedure (skin) | 90 min | in_clinic | 360.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 12 · i10: 10
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.5246/euroclin.2025.0 · PMID: 33245157 · cited by 9
-
European registry analysis of Oncology outcomes
DOI: 10.8120/euroclin.2024.1 · PMID: 38168448 · cited by 11
-
Outcomes of Oncology in adults — a multi-centre cohort
DOI: 10.1819/euroclin.2023.2 · PMID: 30684374 · cited by 13
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
- 🏆 Young Investigator Award · European Society · 2023 · international
Society memberships
- WONCA Europe — Family Doctors — Member · since 2013
- national college of family doctors — Member · since 2013
- European Union of Medical Specialists (UEMS) — Member · since 2013
Patient reviews
- Bedside Manner
- 5.00
- Knowledge
- 5.00
- Wait Time
- 4.75
- Staff Friendliness
- 5.00
- Ease Of Appointment
- 4.90
- Value For Money
- 4.92
- Would Recommend Pct
- 99
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · professor.mark.beresford@euroclinics.example
- Accepted intl insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
